Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Devangi Shah"'
Autor:
Sabrina N. Copsel, Casey O. Lightbourn, Henry Barreras, Ines Lohse, Dietlinde Wolf, Cameron S. Bader, John Manov, Brandon J. Kale, Devangi Shah, Shaun P. Brothers, Victor L. Perez, Krishna V. Komanduri, Claes Wahlestedt, Robert B. Levy
Publikováno v:
Frontiers in Immunology, Vol 9 (2019)
A recent approach for limiting production of pro-inflammatory cytokines has been to target bromodomain and extra-terminal (BET) proteins. These epigenetic readers of histone acetylation regulate transcription of genes involved in inflammation, cardio
Externí odkaz:
https://doaj.org/article/9cc5a389d4de4657b305b7b1c9f3af61
Publikováno v:
Journal of pediatric hematology/oncology. 44(7)
Adolescent and young adult (AYA) cancer survivors experience treatment-related late effects so guidelines recommend providing a treatment summary, yearly follow-up, and risk-adapted testing. AYA survivors' knowledge of surveillance follow-up was stud
Autor:
Asha Pillai, Jumana Ashy, Gregory Suhrheinrich, Julio C. Barredo, Edward Ziga, Warren Alperstein, Devangi Shah, Jennifer Reichbach
Publikováno v:
Transplantation and Cellular Therapy. 27:S278-S279
Autor:
Sabrina Copsel, Casey O. Lightbourn, Henry Barreras, Ines Lohse, Dietlinde Wolf, Cameron S. Bader, John Manov, Brandon Kale, Devangi Shah, Shaun Brothers, Victor L Perez, Krishna V. Komanduri, Claes Wahlestedt, Robert B. Levy
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S25-S26
Targeting bromodomain and extra-terminal (BET) proteins has recently provided a useful approach for limiting production of pro-inflammatory cytokines. These epigenetic readers regulate transcription of genes involved in inflammation and cancer. Devel
Autor:
Asha Pillai, Edward Ziga, Gregory Suhrheinrich, Devangi Shah, Jennifer Reichbach Douglas, Julio C. Barredo, Jumana Ashy, Warren Alperstein
Publikováno v:
Blood. 134:5680-5680
Background Graft vs Host Disease (GVHD) is a common but revered complication after allogenic hematopoietic stem cell transplants (HSCT). Corticosteroids are the first-line therapy for GVHD, yet a consensus is lacking for second-line therapy in patien
Autor:
Brent J. Pfeiffer, Devangi Shah, Krishna V. Komanduri, Robert B. Levy, John J. Manov, Casey O. Lightbourn, Henry Barreras, Claes Wahlestedt, Dietlinde Wolf, Sabrina Copsel, Cameron S. Bader
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S363